Viewing Study NCT00338416

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 11:48 AM
Ignite Modification Date: 2026-02-28 @ 6:33 PM
Study NCT ID: NCT00338416
Status: COMPLETED
Last Update Posted: 2011-06-10
First Post: 2006-06-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cancer View
None Anemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Chemotherapy Induced Anemia View
None PROCRIT (Epoetin alfa) View
None Chemotherapy View
None Epoetin alfa View